3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 1/2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Conditions
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Recurrence
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Interventions
pembrolizumab
9
trastuzumab deruxtecan
5
trametinib
4
dabrafenib
4
zanubrutinib
3
nilotinib
3
fludarabine
3
Trastuzumab
3
Dexamethasone
3
Cyclophosphamide
3
tucatinib
2
tisagenlecleucel
2
selinexor
2
relatlimab
2
pemigatinib
2
larotrectinib
2
ipatasertib
2
erdafitinib
2
entrectinib
2
enfortumab vedotin
2
defactinib
2
daratumumab
2
blinatumomab
2
binimetinib
2
belzutifan
2
axicabtagene ciloleucel
2
atezolizumab
2
TIC10 compound
2
Sunitinib
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Has announcements
×
fludarabine
×
Clear all
NCT02601313
2026-03-18
ZUMA-2
Gilead Sciences
Phase 2
Completed
105 enrolled
33 charts
1 FDA
NCT03105336
2025-12-23
ZUMA-5
Gilead Sciences
Phase 2
Completed
159 enrolled
27 charts
1 FDA
NCT04245839
2025-11-05
TRANSCEND FL
Celgene
Phase 2
Active not recruiting
276 enrolled
2 FDA